NCT04480788 - CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 24, 2020

Primary Completion Date

August 1, 2022

Study Completion Date

August 31, 2022

Conditions

T Lymphoblastic Leukemia/LymphomaExtramedullary NK-T-cell Lymphoma, Nasal TypePeripheral T-cell Lymphoma, NonspecificAngioimmunoblastic T-cell LymphomaEnteropathy-Associated T-Cell LymphomaAnaplastic Large Cell Lymphoma, ALK-negativeT-cell Lymphoblastic Leukemia

Interventions

BIOLOGICAL

T cell injection targeting CD7 chimeric antigen receptor

Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation

Trial Locations (1)

450000

RECRUITING

First Affiliated Hospital of Zhengzhou University, Zhengzhou